# Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

> clinical trial · VERIFIED · 2026-06-22

Status: WITHDRAWN · Sponsor: Novartis Pharmaceuticals · Condition: Advanced HR+/HER2- Breast Cancer

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07570966

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.